March 2018 Cancer Epidemiology Matters E-News

Cancer Epidemiology Matters E-News

March 2018

The 2018 AACR Annual Meeting: 19 Sessions for Epidemiologists

EGRP staff are available to meet with investigators during Meet-the-Experts sessions in the NCI exhibit booth (#1400). See schedule below. Photo courtesy of the National Cancer Institute.

The 109th Annual Meeting of the American Association for Cancer ResearchExternal Web Site Policy (AACR) will take place from April 14-18, 2018 in Chicago, IL. To help attendees make the most of their time at this year's meeting, the Epidemiology and Genomics Research Program (EGRP) has assembled a list of selected oral presentations by National Cancer Institute (NCI) staff and grantees that highlight important resources and topics in cancer epidemiology and genomics, funding opportunities, and grantsmanship issues. If you are attending AACR this year, remember to add these sessions to your personal meeting itineraryExternal Web Site Policy before you go.

For more epidemiology sessions during the conference, check out MEG at the Annual MeetingExternal Web Site Policy, a list compiled by AACR's Molecular Epidemiology Interest Group, and the Epidemiology TrackExternal Web Site Policy in the AACR Annual Meeting Online Itinerary PlannerExternal Web Site Policy.

View Selected AACR Sessions
Note: Click to expand.

Saturday, April 14
Time Topics
10:15 a.m. – 12:15 p.m.

Computational Methods for Cancer Genomics ResearchExternal Web Site Policy

This session features the Head of the Cancer Biology and Genomics Section in NCI’s Center for Biomedical Informatics and Information Technology and grantees supported by the Informatics Technology and Cancer Research (ITCR) program.
10:15 a.m. – 12:15 p.m.

Old and New Puzzles in the Genetic Epidemiology of CancerExternal Web Site Policy

This session includes a presentation by staff in NCI’s Division of Cancer Epidemiology and Genetics; it is chaired by and includes presentations from EGRP grantees.
1:00 p.m. - 3:00 p.m.

Cancer Prevention and Early Diagnosis in Low and Middle-Income Countries (LMICs)External Web Site Policy

This session includes a presentation by an investigator funded by the Division of Cancer Control and Population Sciences (DCCPS).
3:15 p.m. – 5:15 p.m.

What Can We Learn about Cancer by Combining Germline and Somatic Data?External Web Site Policy

This session includes a presentation by an EGRP grantee.
3:15 p.m. – 5:15 p.m.

The Paradox Toolbox: Developing a Better Understanding of Associations between Obesity and Cancer – and What to Do about It?External Web Site Policy

This session is being chaired by an EGRP grantee.

Sunday, April 15
Time Topics
7:00 a.m. - 8:00 a.m.

NIH Grants Session: Changes in Review, Funding, and Funding Opportunities at the NCIExternal Web Site Policy

This session is chaired by the Deputy Director of NCI’s Division of Cancer Biology and features a presentation by the chief of a review group at NIH’s Center for Scientific Review.
12:15 p.m. - 1:45 p.m.

NCI Sponsored Training Awards and OpportunitiesExternal Web Site Policy

This session features staff from NCI’s Center for Cancer Training.
1:15 p.m. - 2:00 p.m.

Molecular Epidemiology Working Group (MEG) Networking Session with Early-Career ResearchersExternal Web Site Policy

This session includes a presentation by Deborah Winn, Ph.D., Deputy Director, DCCPS and is being chaired by an EGRP grantee.
3:15 p.m. - 4:45 p.m.

NIH-Supported Infrastructure and Resources to Support Metabolomics ResearchExternal Web Site Policy

This session is being moderated by and includes a presentation by EGRP's Krista Zanetti, Ph.D., M.P.H., R.D., Program Director, Genomic Epidemiology Branch and by staff in NCI’s Division of Cancer Biology.

Monday, April 16
Time Topics
9:00 a.m. – 9:30 a.m.

Meet-the-Expert Session: Implementing NIH Data-Sharing Policies

This session features Emily Harris, Ph.D., M.P.H., Deputy Associate Director, EGRP. It will take place in NCI’s exhibit booth (#1400).
10:30 a.m. - 12:15 p.m.

NCI Initiatives Generating, Translating and Sharing “Omics” Data to Advance Precision OncologyExternal Web Site Policy

This session includes staff from NCI’s Center for Cancer Genomics and Center for Strategic Scientific Initiatives.
12:15 p.m. - 1:45 p.m.

The NCI Cancer Research Data CommonsExternal Web Site Policy

This session features staff from NCI’s Center for Biomedical Informatics and Information Technology.
3:00 p.m. – 5:00 p.m.

Genetic and Molecular Epidemiology of Cancer Risk and PrognosisExternal Web Site Policy

This session is chaired by an investigator in NCI’s Division of Cancer Epidemiology and Genetics and features research conducted by several EGRP grantees.
6:30 p.m. - 8:00 p.m.

Molecular Epidemiology Working Group (MEG) Town Hall Meeting and Networking ReceptionExternal Web Site Policy

This session will include a presentation by EGRP's Leah Mechanic, Ph.D., M.P.H., Program Director, Genomic Epidemiology Branch, a Scientific Review Officer from NIH’s Center for Scientific Review, and several EGRP grantees.

Tuesday, April 17
Time Topics
10:30 a.m. – 12:30 p.m.

Funding Opportunities for Cancer Research at Multiple NIH Institutes and CentersExternal Web Site Policy

This session will include a presentation by Mukesh Verma, Ph.D., Chief of EGRP’s Methods and Technologies Branch, as well as staff from NCI’s Division of Cancer Treatment and Diagnosis and the National Institute on Alcohol Abuse and Alcoholism, the National Institute of Environmental Health Sciences, National Institute of Dental and Craniofacial Research, the National Institute on Minority Health and Health Disparities, the National Institute of General Medical Sciences, and the Center for Scientific Review.
1:00 p.m. – 2:45 p.m.

Improvement in the Understanding of Global Health Disparities: Ongoing and Recommended SolutionsExternal Web Site Policy

This session features a presentation by an EGRP grantee.
3:00 p.m. – 3:30 p.m.

Meet-the-Expert Session: Social Epigenomic Approaches in Health Disparity

This session will feature EGRP's Mukesh Verma, Ph.D., Chief of EGRP’s Methods and Technologies Branch. It will take place in NCI’s exhibit booth (#1400).
3:00 p.m. – 5:00 p.m.

Endogenous and Exogenous Factors in Cancer Risk and MortalityExternal Web Site Policy

This session features research conducted by several EGRP grantees.

Wednesday, April 18
Time Topics
10:00 a.m. – 10:30 a.m.

Meet-the-Expert Session: Collaborative Technology Opportunities to Advance Molecular Epidemiology

This session will feature EGRP's Rao L. Divi, Ph.D., Program Director, Methods and Technologies Branch. It will take place in NCI’s exhibit booth (#1400).


New NCI Funding Opportunities in Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility

The 2016 Annual Report to the Nation on the Status of CancerExternal Web Site Policy featured the increasing incidence of liver cancer and deaths from liver cancer. Viral hepatitis and alcohol abuse contribute significantly to liver cancer etiology in the United States. Little is known, however, about the independent role of emerging non-viral factors in liver carcinogenesis or how they may interact with viral hepatitis or serve as a co-factor to increase susceptibility. Therefore, NCI has developed a set of funding opportunity announcements (FOAs)-- Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility-- using the R01 mechanism (PA-18-677) and the R21 mechanism (PA-18-678), to stimulate research on the role of non-viral risk factors in liver cancer (hepatocellular carcinoma [HCC] and other subtypes) susceptibility.

The overarching objective of PA-18-677 and PA-18-678 is to enhance population-based research on liver cancer. Specifically, this set of FOAs seeks to support epidemiologic research in expanding our understanding of the etiology of the malignancy, including exploring emerging and novel risk factors that may contribute to the rising burden of liver cancer in the U.S. and expanding investigations on unanswered questions related to viral hepatitis-associated liver cancer. The funded projects will contribute to the body of evidence needed to inform evidence-based prevention and control strategies of liver cancer. The FOAs support research on HCC, the most common subtype of liver cancer, and also include support of applications seeking to better understand the etiology of other histological subtypes such as cholangiocarcinoma, hepatoblastoma, and angiosarcoma of liver.

Approximately 15%-50% of U.S.-based HCC cases do not have evidence of viral hepatitis or heavy alcohol consumption as risk factors. The etiology of cholangiocarcinoma in the U.S. is also unclear, as the prevalence of liver fluke, an established risk factor found more commonly in Thailand, is extremely low. Recent epidemiologic evidence suggests that non-viral factors may contribute independently and/or in concert with viral hepatitis to the observed increase in liver cancer incidence. These non-viral factors include non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), obesity, diabetes, metabolic syndrome, and others.

Additionally, novel hypotheses of underlying liver carcinogenesis have emerged in recent years. They include the influence of the microbiome in the liver-gut axis on liver-related malignancies, microvesicles as a potential biomarker, the potential etiologic influence of environmental exposures such as ambient air pollution, the role that social and contextual drivers play in the differential incidence and mortality rates observed across U.S. regions and populations, and the influence of the circulating immune system on liver cancer risk and progression. These FOAs on liver cancer susceptibility collectively support scientific inquiries on these novel areas and others in liver cancer research.

For more information regarding important dates, application requirements, and other questions for these funding opportunities, see PA-18-677 and PA-18-678 or contact Tram Kim Lam, Ph.D., M.P.H., Program Director in the Epidemiology and Genomics Research Program's Environmental Epidemiology Branch.

For additional funding opportunities supporting liver cancer research, please see:

  • RFA-CA-17-025 (U01): Consortium on Translational Research in Early Detection of Liver Cancer: Translational Research Centers, and
  • PAR-17-150 (R21) and PAR-17-151 (R01): Mechanisms of Disparities in Chronic Liver Diseases and Cancer

Funding Opportunities

  • Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33, Clinical Trial Not Allowed)
  • Innovative Basic Research on Adducts in Cancer Risk Identification and Prevention (Clinical Trial Not Allowed, R01, R21)
  • Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21, Clinical Trial Not Allowed)
  • Notice of Change to PAR-17-233 Core Infrastructure and Methodological Research for Cancer Epidemiology Cohorts (U01)
  • Research Answers to National Cancer Institute's (NCI) Provocative Questions (Clinical Trial Optional, R01, R21)
  • Research on the Health of Women of Understudied, Underrepresented and Underreported Populations (Admin Supp – Clinical Trial Optional)

Requests for Information

Return to Top